Gaviscon "floating" claim
Marion's NDA for Gaviscon, includes alginic acid as an inactive ingredient as well as "floating" claim in the product's labeling. FDA recently denied a long-pending petition from Marion to amend the antacid OTC monograph to include both alginic acid and the floating claim. That rejection effectively blocks other firms from entering the market with products containing alginic acid via the monograph.
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.